Groundbreaking Agreement Makes Hep-C Cure Affordable to pts With HIV

PROF.DRRAM ,HIV/AIDS,SEX Diseases,Deaddiction & Hepatitis Expert 
profdrram@gmail.com,+917838059592,+919832025033,DELHI,INDIA
HIV/ AIDS,CANCER MODERN MEDICINES AVAILABLE AT CHEAP RATE.
FOLLOW ON FACE BOOK:www.facebook.com/ramkumar 
FOLLOW ON TWITTER:www.twitter.com/profdrram
Pharmaceutical company AbbVie has deeply discounted their new drug Viekira Pak, the first three-in-one treatment chronic hepatitis C in those living with HIV.The National Alliance of State and Territorial AIDS Directors has announced a groundbreaking agreement to make a hepatitis C cure more financially accessible to those with HIV by reaching a new pricing agreement with the biopharmaceutical company AbbVie for Viekira Pak to treat chronic hepatitis C in those living with HIV.

Viekira Pak (which co-packages ombitasvir, paritaprevir, and ritonavir tablets with dasabuvir tablets) is the only FDA-approved regimen that contains three mechanisms of action (an inhibitor, a protease inhibitor, and a non-nucleoside polymerase inhibitor). These antiviral agents work together to attack the virus at three separate stages of the disease’s lifecycle and acheive a practical cure after 12 weeks of treatment.

Hepatitis C is a liver disease that can become a lifelong chronic illness and is of particular concern for HIV positive people. According to the CDC, “About one quarter of HIV-infected persons in the United States are also infected with Hepatitis C virus (HCV). HCV is a bloodborne virus transmitted through direct contact with the blood of an infected person. Thus, coinfection with HIV and HCV is common…HCV infection progresses more rapidly to liver damage in HIV-infected persons. HCV infection may also impact the course and management of HIV infection.”

AbbVie is the first drug manufacturer to offer a discount on the AIDS Drug Assistance Program (ADAP) price of a medication to treat the hepatitis C virus, which is especially important when it comes to new curative HCV treatments. Even with these discounts and rebates, many AIDS drug assistant programs may remain unable to add Viekira Pak to their formularies because of its high cost. Still, this agreement is important because it recognizes that access to hepatitis C medications is an issue for people living with HIV. Furthermore, it demonstrates to other pharmaceutical companies that lowering their prices can increase the likelihood of their medication being included on the statewide ADAP lists of approved medications.

ADAP make their own decisions about which new medications to add to their formularies, but since 2003, the ADAP Task Force has collaborated with pharmaceutical companies to provide ADAPs access to discounted pricing on HIV drugs.

Hailing the negotiated pricing, NASTAD, notes, “Hepatitis is the leading cause of non-AIDS-related death in people co-infected with HIV and hepatitis. Co-infection of HIV and HCV increases the progression of liver disease and can occur without symptoms.”

These drug assistance programs, which gain funding via the Ryan White Program, can only provide services and medications for individuals who are living with HIV, not those who merely have Hep C. What makes Viekira Pak unique is that it was approved with a co-infection indication—in other words, it can be prescribed to those with HIV and HCV, and HIV funding can be used pay for the medication.

There is no vaccine for Hep C, but a new class of HCV medications are being hailed as a cure. Viekira Pak’s own FDA approval was based on the results of clinical trials which showed that Viekira Pak cured 92 percent of patients coinfected with HIV and HCV.

Still these currative regimes are often quite expensive and must be taken for 12 weeks to achieve these results. Gilead's Sovaldi has come under attack for its extremely high pricing, reportedly around $84,000 for a 12 week treatment; without this ADAP agreement, Viekira Pak is around $83,000. Which makes AbbVie voluntarily negotiated price cut such an important step.